Talazoparib with chemotherapy for relapsed childhood AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years old or younger
- You have relapsed or refractory AML (or certain rare acute leukemia types)
- You have had a stem cell transplant more than 60 days ago (if you had one)
- You are well enough to take treatment: heart function, kidney, liver tests, and overall activity score meet limits
- Enough time has passed since your last treatments, and side effects are mostly gone (grade 0–1)
- Your white blood cell count is not too high (WBC 50,000 or less)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving special immune cells (NK cells) along with a PARP inhibitor can help people with acute myeloid leukemia (AML). It focuses on people whose AML is coming back or not fully responding, and who have certain lab signs that help show the disease is still active.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This early-phase study tests whether tazemetostat and palbociclib can help people with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It looks for safety and early signs of how well the treatment works.
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.